OR WAIT null SECS
March 06, 2024
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
March 02, 2024
Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.
March 01, 2024
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
The agency has recommended granting marketing authorization to ALS treatment, Qalsody (tofersen), for adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.